Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

[1]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[2]  K. Aldape,et al.  RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. J. van den Bent,et al.  First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. , 2011, Neuro-oncology.

[4]  Xin Li,et al.  Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. , 2011, Neuro-oncology.

[5]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Uhm.  Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule: The “Rescue” Approach , 2009 .

[9]  M. Christmann,et al.  Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. , 2008, Molecular medicine reports.

[10]  S. Turazzi,et al.  Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas , 2008, Journal of Neuro-Oncology.

[11]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[12]  A. Brandes,et al.  Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas , 2008, Journal of Neuro-Oncology.

[13]  J. Menten,et al.  A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma , 2008, Cancer investigation.

[14]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Pouratian,et al.  Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas , 2007, Journal of Neuro-Oncology.

[16]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[17]  M. J. van den Bent,et al.  1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. , 2006, European journal of cancer.

[18]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[20]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[21]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Sepkowitz,et al.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[24]  M. J. van den Bent,et al.  Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Brandes,et al.  Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study , 2002, Oncology.

[26]  S. Gerson.  Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[28]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[30]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[31]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.